Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with
liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration
as minimal HE (MHE), covert HE (grade I), or overt HE (OHE, grade II-IV). Liver cirrhosis is
the most common cause of portal hypertension (PH). Patients who develop complications of PH,
like variceal bleeding or refractory ascites, can benefit from a Transjugular Intrahepatic
Portosystemic Shunt (TIPS) placement. Unfortunately, post-TIPS HE is a common and often
severe complication. Incidence of new onset or worsening of HE after TIPS is approximately
20-45%. Currently there is no strategy to prevent post-TIPS HE.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
Erasmus Medical Center Leiden University Medical Center Maastricht University Medical Center Norgine Radboud University Universitaire Ziekenhuizen Leuven University Medical Center Groningen